CYP19A1 and breast carcinoma: Data from the Western blot analysis revealed that DOI (2.5 and 5 mg/kg) treatment upregulated aromatase in the ovary (Fig. 6c), but not in breast tissue (Fig. 6e) or MCF-7 breast cancer cells (Fig. 7f).